Christopher Bunick, MD, PhD, and Chinweike Ukomadu, MD, PhD, discuss late-breaking phase 3 findings at AAD highlighting high rates of clearance and favorable safety with once-daily oral zasocitinib.
Chinweike Ukomadu, MD, PhD
Advertisement
Chinweike Ukomadu, MD, PhD, is the Senior Vice President and Head of Gastrointestinal and Inflammation Therapeutic Area Unit at Takeda.
Articles by Chinweike Ukomadu, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
Digital Twins in Dermatology: Your Patient’s Virtual Double Is Coming
3
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
4
Moving Past Dermal Filler Trends to Focus on Healthy Skin Aging
5